EGFR and interstitial lung disease: Targeted therapy, such as ErbB receptor tyrosine kinase inhibitor (EGFR-TKI), although the incidence of ILD caused by EGFR-TKI is not high, once it occurs, it can seriously threaten the life of patients [25].